Cargando…
Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a common metabolic disease that affects 20–30% of individuals worldwide. Liver puncture remains the gold standard for the diagnosis of liver diseases despite limitations regarding invasive nature and sample variability. It is of great clinical...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050915/ https://www.ncbi.nlm.nih.gov/pubmed/33858428 http://dx.doi.org/10.1186/s12967-021-02820-7 |
_version_ | 1783679661291601920 |
---|---|
author | Hu, Cheng Wang, Tao Zhuang, Xiaoyu Sun, Qiaoli Wang, Xiaochun Lin, Hui Feng, Mingli Zhang, Jiaqi Cao, Qin Jiang, Yuanye |
author_facet | Hu, Cheng Wang, Tao Zhuang, Xiaoyu Sun, Qiaoli Wang, Xiaochun Lin, Hui Feng, Mingli Zhang, Jiaqi Cao, Qin Jiang, Yuanye |
author_sort | Hu, Cheng |
collection | PubMed |
description | BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a common metabolic disease that affects 20–30% of individuals worldwide. Liver puncture remains the gold standard for the diagnosis of liver diseases despite limitations regarding invasive nature and sample variability. It is of great clinical significance to find noninvasive biomarkers to detect and predict NAFLD. OBJECTIVE: The aims of this study were to identify potential serum markers in individuals with early-stage NAFLD and to advance the mechanistic understanding of this disease using a high-throughput mass spectrometry-based untargeted metabolomics approach. METHODS: One hundred and twelve patients with early-stage NAFLD aged 18–55 were recruited according to the guidelines. The control group included 112 healthy participants. The demographic, anthropometric, clinical and laboratory data of all participants were systematically collected. Serum samples were obtained after an overnight fast. The comprehensive serum metabolomic analysis was performed by ultra-performance liquid chromatography-Orbitrap mass spectrometry. The resultant data was processed by Compound Discover and SIMCA-P software to validate the potential biomarkers. Significantly altered metabolites were evaluated by variable importance in projection value (VIP > 1) and ANOVA (p < 0.01). Pathway analysis was performed using MetaboAnalyst 4.0. RESULTS: The liver function test of early NAFLD patients showed no statistical differences to control group (p > 0.05). However, obvious differences in blood lipids were observed between subjects with NAFLD and controls (p < 0.001). In total, 55 metabolites showed significant changes in experimental group were identified. The area under curve (AUC) values deduced by receiver operating curve (ROC) analysis indicated that these newly identified biomarkers have high predictability and reliability. Of these, 15 metabolites with AUC greater than 0.9 were of great diagnostic value in early NAFLD patients. CONCLUSION: In this study, a total of 15 serum metabolites were found to strongly associate with early NAFLD. These biomarkers may have great clinical significance in the early diagnosis of NAFLD, as well as to follow response to therapeutic interventions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02820-7. |
format | Online Article Text |
id | pubmed-8050915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80509152021-04-19 Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry Hu, Cheng Wang, Tao Zhuang, Xiaoyu Sun, Qiaoli Wang, Xiaochun Lin, Hui Feng, Mingli Zhang, Jiaqi Cao, Qin Jiang, Yuanye J Transl Med Research BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a common metabolic disease that affects 20–30% of individuals worldwide. Liver puncture remains the gold standard for the diagnosis of liver diseases despite limitations regarding invasive nature and sample variability. It is of great clinical significance to find noninvasive biomarkers to detect and predict NAFLD. OBJECTIVE: The aims of this study were to identify potential serum markers in individuals with early-stage NAFLD and to advance the mechanistic understanding of this disease using a high-throughput mass spectrometry-based untargeted metabolomics approach. METHODS: One hundred and twelve patients with early-stage NAFLD aged 18–55 were recruited according to the guidelines. The control group included 112 healthy participants. The demographic, anthropometric, clinical and laboratory data of all participants were systematically collected. Serum samples were obtained after an overnight fast. The comprehensive serum metabolomic analysis was performed by ultra-performance liquid chromatography-Orbitrap mass spectrometry. The resultant data was processed by Compound Discover and SIMCA-P software to validate the potential biomarkers. Significantly altered metabolites were evaluated by variable importance in projection value (VIP > 1) and ANOVA (p < 0.01). Pathway analysis was performed using MetaboAnalyst 4.0. RESULTS: The liver function test of early NAFLD patients showed no statistical differences to control group (p > 0.05). However, obvious differences in blood lipids were observed between subjects with NAFLD and controls (p < 0.001). In total, 55 metabolites showed significant changes in experimental group were identified. The area under curve (AUC) values deduced by receiver operating curve (ROC) analysis indicated that these newly identified biomarkers have high predictability and reliability. Of these, 15 metabolites with AUC greater than 0.9 were of great diagnostic value in early NAFLD patients. CONCLUSION: In this study, a total of 15 serum metabolites were found to strongly associate with early NAFLD. These biomarkers may have great clinical significance in the early diagnosis of NAFLD, as well as to follow response to therapeutic interventions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02820-7. BioMed Central 2021-04-15 /pmc/articles/PMC8050915/ /pubmed/33858428 http://dx.doi.org/10.1186/s12967-021-02820-7 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Hu, Cheng Wang, Tao Zhuang, Xiaoyu Sun, Qiaoli Wang, Xiaochun Lin, Hui Feng, Mingli Zhang, Jiaqi Cao, Qin Jiang, Yuanye Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry |
title | Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry |
title_full | Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry |
title_fullStr | Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry |
title_full_unstemmed | Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry |
title_short | Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry |
title_sort | metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050915/ https://www.ncbi.nlm.nih.gov/pubmed/33858428 http://dx.doi.org/10.1186/s12967-021-02820-7 |
work_keys_str_mv | AT hucheng metabolicanalysisofearlynonalcoholicfattyliverdiseaseinhumansusingliquidchromatographymassspectrometry AT wangtao metabolicanalysisofearlynonalcoholicfattyliverdiseaseinhumansusingliquidchromatographymassspectrometry AT zhuangxiaoyu metabolicanalysisofearlynonalcoholicfattyliverdiseaseinhumansusingliquidchromatographymassspectrometry AT sunqiaoli metabolicanalysisofearlynonalcoholicfattyliverdiseaseinhumansusingliquidchromatographymassspectrometry AT wangxiaochun metabolicanalysisofearlynonalcoholicfattyliverdiseaseinhumansusingliquidchromatographymassspectrometry AT linhui metabolicanalysisofearlynonalcoholicfattyliverdiseaseinhumansusingliquidchromatographymassspectrometry AT fengmingli metabolicanalysisofearlynonalcoholicfattyliverdiseaseinhumansusingliquidchromatographymassspectrometry AT zhangjiaqi metabolicanalysisofearlynonalcoholicfattyliverdiseaseinhumansusingliquidchromatographymassspectrometry AT caoqin metabolicanalysisofearlynonalcoholicfattyliverdiseaseinhumansusingliquidchromatographymassspectrometry AT jiangyuanye metabolicanalysisofearlynonalcoholicfattyliverdiseaseinhumansusingliquidchromatographymassspectrometry |